Avloquin-H^®

Avloquin-H^® is the preparation of Hydroxychloroquine Sulfate which is synthetically produced version of quinine. It acts as an immunosuppressant by inhibiting production of rheumatoid and acute phase reactants. It also accumulates in white blood cells, stabilizing lysosomal membranes and inhibiting the activity of many enzymes, including collagenase and the proteases that cause cartilage breakdown. It also acts by disrupting cell walls of infected red blood cells and kills the developing parasites.

No Data

Avloquin-H^® is indicated for-

• Acute and chronic rheumatoid arthritis
• Systemic lupus erythematosus (SLE)
• Malaria

Route of administration: Avloquin-H^® tablets are for oral administration and are taken with food to avoid stomach upset.

Acute and chronic rheumatoid arthritis: 400 to 600 mg daily. When good response is obtained (usually 4 to 8 weeks), dose can be reduced to 50%.

Systemic lupus erythematosus (SLE): 400 mg once or twice daily for several weeks or months depending on response of the patients. Maintenance dose is 200 to 400 mg daily.

Malaria: In adults, an initial dose of 800 mg followed by 400 mg in 6-8 hours and 400 mg on each of two consecutive days. For children a total dose representing 25 mg/kg is administered in 3 days as follows. First dose: 10 mg base/kg (but not exceeding a single dose of 620 mg base). Second dose: 5 mg base/kg (but not exceeding a single dose of 310 mg base) 6 hours after first dose. Third dose: 5 mg base/kg 18 hours after second dose. Fourth dose: 5 mg base/kg 24 hours after third dose.

* Hydroxychloroquine sulfate USP 200 mg equivalent to 155 mg of base.

Use in pregnancy and lactation
During pregnancy, this drug should be used only if clearly needed. Since small amounts of this medication are found in breast milk consult to the physician before using the medication.

Use in children and adolescents
The use in children and adolescents is given in dose and administration section.

Children are specially sensitive to the 4-aminoquinolone compounds. Patients should be strongly warned to keep these drugs out of the reach of children. Ophthalmologic examination requires in every 12 months.

Generally hydroxychloroquine sulfate is well tolerated. However, few side effects like nausea, vomiting, stomach upset, loss of appetite, diarrhea, tiredness, weakness or headache and visual problem may occur in the first several days.

Hydroxychloroquine sulfate is contraindicated in patients with known hypersensitivity to hydroxychloroquine or any other components of this product.

Drug interaction with medication: Hydroxychloroquine sulfate may interact with digoxin, insulin or antidiabetic drugs, mefloquine, antiepileptics, methotrexate and cyclosporine.

Drug interaction with food and others: Not applicable.

Symptoms of overdose consist of headache, drowsiness, visual disturbances, cardiovascular collapse and convulsions followed by sudden and early respiratory and cardiac arrest. Gastric lavage until the stomach is completely emptied.

No Data

Store in a cool (below 30°C) and dry place protected from light. Keep away from the reach of children.

Avloquin-H^® tablet: Each coated tablet contains Hydroxychloroquine Sulfate USP 200 mg.

Avloquin-H^® tablet: Carton of 30 tablets in blister pack.